New drug combo aims to outsmart resistant cancers

NCT ID NCT05082259

Ongoing Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight cancer. About 61 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASTX660 (Tolinapant) and Pembrolizumab
What this could lead to: If successful, this could point toward a new combination therapy for cancers that don't respond to current treatments.
What could go wrong: This is an early Phase 1 trial with only 61 participants, so safety and dosing are still being figured out. It may not work in larger groups or for all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cervical cancer glioblastoma hormone receptor-positive breast cancer neoplasm triple-negative breast carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER CERVICAL CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Cambridge University Hospitals NHS Trust

Cambridge, CB2 0QQ, United Kingdom
The Royal Marden NHS Foundation Trust - Drug Development Unit

Sutton, SM2 5PT, United Kingdom
The Royal Marsden NHS Foundation Trust - Breast Unit

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.